Sugi Predict

Sugi Predict / Targets / P2RX2

P2RX2

P2X purinoceptor 2 · Q9UBL9 · P2RX2 on Sugi Atlas →

38,491 patent compounds predicted against P2RX2, 22,220 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL310444 SCHEMBL310444 1.00 19/20
SCHEMBL310823 SCHEMBL310823 1.00 19/20
SCHEMBL310997 SCHEMBL310997 1.00 19/20
SCHEMBL311221 SCHEMBL311221 1.00 19/20
SCHEMBL311216 SCHEMBL311216 1.00 18/20
SCHEMBL311816 SCHEMBL311816 1.00 18/20
SCHEMBL312096 SCHEMBL312096 1.00 18/20
SCHEMBL310920 SCHEMBL310920 0.77 18/20
SCHEMBL357080 SCHEMBL357080 0.61 18/20
SCHEMBL357564 SCHEMBL357564 0.61 18/20
SCHEMBL409750 SCHEMBL409750 0.57 18/20
SCHEMBL357731 SCHEMBL357731 0.51 18/20
SCHEMBL358473 SCHEMBL358473 0.51 18/20
SCHEMBL451623 SCHEMBL451623 0.49 18/20
SCHEMBL310360 SCHEMBL310360 1.00 17/20
SCHEMBL311122 SCHEMBL311122 1.00 17/20
SCHEMBL312462 SCHEMBL312462 1.00 17/20
SCHEMBL639011 SCHEMBL639011 1.00 17/20
SCHEMBL357414 SCHEMBL357414 0.61 17/20
SCHEMBL357412 SCHEMBL357412 0.59 17/20

Clinical trials — most relevant to P2RX2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine PHASE4COMPLETED
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel PHASE4COMPLETED
The Role of Orexin in Human Panic Disorder PHASE4COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest PHASE4UNKNOWN
Pre-operative Ketorolac Administration Has no Pre-emptive Analgesic Effect Following Total Abdominal Hysterectomy PHASE4COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease PHASE2/PHASE3COMPLETED
Botulinum Toxin Injections for Oral Neuropathic Pain PHASE3COMPLETED
Clopidogrel and Response Variability Investigation Study 2 PHASE3COMPLETED
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial PHASE1/PHASE2COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects PHASE1COMPLETED
A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383 PHASE1UNKNOWN
First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160. PHASE1COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults EARLY_PHASE1COMPLETED
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients nanRECRUITING
Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients nanCOMPLETED
An Investigation Into the Mechanism of Inhalation Cough Challenge nanCOMPLETED
ATP and P2X3 Receptor in Chronic Cough nanUNKNOWN
Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis nanRECRUITING
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors nanCOMPLETED
Effect of Botulinum Toxin A on Neurogenic Detrusor Overactivity in Chronic Spinal Cord Injured Patients nanCOMPLETED
Neurogenic Mechanisms in Burning Mouth Syndrome nanCOMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Visceral Afferents nanWITHDRAWN
Suppressive Functions of Regulatory T Cells in Migraine nanNOT_YET_RECRUITING
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder nanCOMPLETED
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy nanENROLLING_BY_INVITATION
Cytokines in Papillon-Lefèvre Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RX2 binder may also engage these)

ProteinNameSimilarity
Q8K3P1 — 1.000 Q8K3P1 →
O70397 — 0.997 O70397 →
P49653 — 0.994 P49653 →
P2RX1 P2X purinoceptor 1 0.977 landscape →
P51576 — 0.975 P51576 →
P47824 — 0.973 P47824 →
Q6S5C2 — 0.970 Q6S5C2 →
Q9EPI0 — 0.970 Q9EPI0 →
ATP6AP1 V-type proton ATPase subunit S1 0.969 landscape →
Q5QQ49 — 0.969 Q5QQ49 →
A0JPH4 — 0.968 A0JPH4 →
Q5T848 — 0.968 Q5T848 →
Q5MNU5 — 0.968 Q5MNU5 →
Q58CS8 — 0.967 Q58CS8 →
Q9JLG8 — 0.967 Q9JLG8 →
Q8TDI7 — 0.967 Q8TDI7 →
Q5QQ51 — 0.966 Q5QQ51 →
Q8IUH8 — 0.966 Q8IUH8 →
D4A6L0 — 0.966 D4A6L0 →
Q80XH4 — 0.966 Q80XH4 →
Q811B1 — 0.966 Q811B1 →
Q9ER64 — 0.965 Q9ER64 →
Q12770 — 0.965 Q12770 →
Q8R4P4 — 0.965 Q8R4P4 →
O76095 — 0.965 O76095 →
E1BBQ2 — 0.965 E1BBQ2 →
Q9H1B5 — 0.965 Q9H1B5 →
Q9H0X9 — 0.965 Q9H0X9 →
A6QM06 — 0.964 A6QM06 →
A7VL23 — 0.964 A7VL23 →